KRAS and pancreatic neoplasm: Emerging preliminary data suggests that NRG1 fusion-bearing malignancies are susceptible to targeting by pan-ERBB/HER small molecule inhibitors (including afatinib) and by antibodies that impact ERBB3/ERRB4 and/or dimerization partners such as ERBB2/HER2 (e.g., zenocutuzumab and seribantumab and, as in our illustrative VCTN1-NRG1 fusion/KRAS wild-type pancreatic cancer patient, with trastuzumab and pertuzumab) (Table 3, Fig. 2).